ATRX and pancreatic neuroendocrine tumor: Recent sequencing studies revealed that pancreatic neuroendocrine tumors (PanNETs) are driven by somatic loss-of-function mutations in epigenetic regulators, with recurrent mutations in MEN1 (38%), DAXX (23%), and ATRX (10%) [10, 11].